Saliva Diagnostic Systems (SALVE) Announces New CEO 
10/19/2005 5:13:15 PM

NEW YORK, April 12 /PRNewswire-FirstCall/ -- Saliva Diagnostics Systems, Inc. (BULLETIN BOARD: SVAD) is pleased to announce the appointment of Mr. Steve Peltzman as CEO, effective March 25, 2005. Mr. Peltzman has been working closely with the Company as a consultant for the last 6 months. Mr. Peltzman has more than thirty years of business experience in technology-based, health-care companies. In 1984, he helped start and served as President and CEO of Applied bioTechnology, Inc. whose cancer business was sold to OSI Pharmaceuticals in 1991, when he became Chief Operating Officer of the consolidated entity; from 1994 through 1997 he served as President and COO of OSIP and remained on its Board of Directors through 1999. From 1980 to 1984, Mr. Peltzman held senior executive positions with Millipore and for ten years preceding that was with Corning Glass Works' Medical diagnostic and device businesses. During the past several years he has been active in several small health care and technology start-ups as their interim CEO or COO or in an advisory capacity to their Boards of Directors.

Mr. Peltzman stated his reasons for joining the firm: "SDS is poised to become a key player in the embryonic, point-of-care, rapid testing market, targeting sexually transmitted and other important infectious diseases. The need to accurately, inexpensively, safely and quickly identify millions of infected individuals throughout the globe is a critical first step in cost effectively dealing with the devastating consequences of HIV, hepatitis and a myriad of other pathogens. SDS's proprietary format for rapid testing appears to be an ideal fit to commercially solve certain of these problems that seriously impact our public health systems and world economies."

About Saliva Diagnostic Systems (SDS)

Saliva Diagnostic Systems manufactures and markets a patented rapid point of care testing device for infectious diseases, as well as oral fluid specimen collection devices using a patented volume adequacy indicator for drugs of abuse testing and other clinical uses. These products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Please visit our website at


Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and the demand for the Company's products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").

Saliva Diagnostics Systems, Inc.

CONTACT: Investor Relations, Saliva Diagnostics Systems, Inc.,+1-508-655-0991